# Conatus Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/conatus-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.conatuspharma.com
- Total disclosed funding: $63M
- Latest round: Series B (Apr 12, 2011)
- Investors on record: 8

## About

Conatus Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for liver diseases by targeting cell death pathways to improve patient outcomes.Founded in 2005 and headquartered in San Diego, US, Conatus Pharmaceuticals specializes in innovative treatments for liver conditions. The company has undergone strategic pivots and raised USD 66 mn in its IPO on July 25, 2013, offering 6 million shares at USD 11 per share. The company has completed 8 deals throughout its operational history.Conatus Pharmaceuticals is engaged in the development of novel therapies aimed at treating liver diseases, with a focus on enhancing liver health through its unique approaches to targeting cellular mechanisms involved in liver damage.In the most recent fiscal year of 2019, Conatus Pharmaceuticals reported a revenue of USD 21.72 mn, alongside an EBITDA of USD -12.14 mn.With the recent IPO funding of USD 66 mn targeted for future development, Conatus Pharmaceuticals is set to expand its therapeutic offerings and research initiatives. The company is focused on launching new products aimed at liver disease management and exploring collaborations to enter new markets by 2025.

## Funding rounds

- Series B, Apr 12, 2011, $7.5M — MPM BioImpact
- Series B, Feb 11, 2011, $20M — Aberdare Ventures, Gilde Healthcare, GeneChem, Bay City Capital, Roche Venture Fund, Advent Life Sciences
- Series A, May 11, 2007, $22M — Aberdare Ventures, Gilde Healthcare, Bay City Capital, Advent Life Sciences
- Series A, Jan 3, 2007, $5.5M — Aberdare Ventures, Gilde Healthcare, Bay City Capital, Advent Life Sciences
- Series A, Nov 30, 2006, $7.9M — Aberdare Ventures, Gilde Healthcare, Advent Venture Partners, Bay City Capital

## Investors

- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series A, Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B
- Advent Venture Partners (https://capitalatlas.ai/funds/advent-venture-partners) — Series A
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A, Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A, Series B
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B